Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

TVRD has been the topic of a number of other reports. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the stock an “equal weight” rating in a report on Monday, October 13th. Piper Sandler downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. BTIG Research cut their target price on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, October 13th. Finally, Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Price Performance

Shares of TVRD stock opened at $4.23 on Tuesday. The stock has a market cap of $39.68 million, a PE ratio of -0.44 and a beta of 0.09. The stock has a 50-day moving average of $4.12 and a 200-day moving average of $18.30. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TVRD. Slate Path Capital LP purchased a new stake in shares of Tvardi Therapeutics during the second quarter worth approximately $16,427,000. Vanguard Group Inc. boosted its stake in shares of Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after purchasing an additional 20,757 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at $4,107,000. Vestal Point Capital LP purchased a new position in Tvardi Therapeutics in the third quarter worth approximately $6,508,000. Finally, Geode Capital Management LLC purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $2,617,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.